Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Pharmaceuticals · CIK 0001232524
$211.97
-0.84% · live
Updated
$13.02B market value
From Jazz Pharmaceuticals plc's FY2025 10-K, filed Feb 24, 2026 · read the filing
Jazz Pharmaceuticals develops and makes medicines. It took in $4.27B last year, which makes it a mid-sized company. It spends more than it earns — losing about 8 cents on every dollar of sales.
The financial picture is mixed, with growth needing attention and profitability and debt weaker.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score 1.58
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Several areas of financial weakness.
From Jazz Pharmaceuticals plc's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$716.6M → -$430.2M
Profit
$560.1M → -$356.1M
Operating margin
17.6% → -10.1%
Profit margin
13.8% → -8.3%
Measured against FY2024, from the 10-K filed Feb 24, 2026
Deteriorated: turned negative
$716.6M to -$430.2MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: turned negative
$560.1M to -$356.1MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
JAZZ fell 0.84% on the latest quote. The average Health Care company tracked here moved +1.63%, and the S&P 500 −1.04%. That is 2.5 points below its sector and in line with the market.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 0% a year for the next 10 years. Over the last 10 years it grew by about 10% a year.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $356.1M last year, losing about 8 cents on every dollar of sales.
Slowly. Sales grew 4.9% last year.
No. At its current cash flow it could clear its debt in about 2.9 years. For every $1 it owes, it owns $1.59 in assets. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $356.1M and generated $1.36B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 24, 2026Filing for FY2025 | FY202410-K · Feb 26, 2025Filing for FY2024 | FY202310-K · Feb 28, 2024Filing for FY2023 | FY202210-K · Mar 1, 2023Filing for FY2022 | FY202110-K · Mar 1, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | +4.9% |
| Selling, general and administrative | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | +30.6% |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M | n/m |
| Operating marginOperating income ÷ revenueWhat is this? | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | −27.7 pts |
| Interest expense | — | — | $32.8M | $32.8M | $89.9M | — |
| Income before tax | -$627.9M | $470.4M | $297.9M | -$372.8M | -$112.8M | n/m |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | n/m |
| Net marginNet income ÷ revenueWhat is this? | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | −22.1 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-5.80 | $9.24 | $6.66 | $-3.54 | $-5.35 | n/m |
† calculated from other reported figures, such as total liabilities as assets minus equity.
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 2,000 shares at $236.40 ($472.8K)
Holds 141,394 shares after this filing.
Sold on the open market — 6,000 shares at $230.33 ($1.4M)
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingWrite down why you are following Jazz Pharmaceuticals plc, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Yahoo Finance ·
Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)
Yahoo Finance ·
Jazz Pharmaceuticals gets Cramer's vote of confidence
Yahoo Finance ·
CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit
Yahoo Finance ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from JAZZ's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 24, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 3.3 | 5/8 | 10-K, filed Feb 24, 2026 |
| FY2024 | 6.0 | 7/8 | 10-K, filed Feb 26, 2025 |
| FY2023 | 6.0 | 6/8 | 10-K, filed Feb 28, 2024 |
| FY2022 | 4.7 | 4/8 | 10-K, filed Mar 1, 2023 |
| FY2021 | 4.7 | 2/8 | 10-K, filed Mar 1, 2022 |
| FY2020 | 8.7 | 5/8 | 10-K, filed Feb 23, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
1.58
In the distress zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −27.7 pts
17.6% to -10.1%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −22.1 pts
13.8% to -8.3%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$9.24 to -$5.80Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -42.3%
$2.41B to $1.39BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +54.3%
$38.1M to $58.8MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: -28.8%
$6.08B to $4.33BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: +1.3%
60.6M to 61.4MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q2 FY2026, from the 10-Q filed Aug 3, 2026 — read it.
Improved: turned positive
-$686.4M to $248.2MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: turned positive
-$718.5M to $192.8MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +86.2 pts
-65.6% to 20.5%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +84.7 pts
-68.7% to 16.0%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: turned positive
-$11.74 to $3.05Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +15.5%
$1.05B to $1.21BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: -23.1%
$4.34B to $3.33BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +36.1%
$1.19B to $1.62BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +3.3%
61.2M to 63.2MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 3, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: −10.9 pts
31.5% to 20.5%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −11.5 pts
27.4% to 16.0%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -26.3%
$336.6M to $248.2MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -34.2%
$293.1M to $192.8MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -35.6%
$4.74 to $3.05Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -22.9%
$4.32B to $3.33BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +13.0%
$1.07B to $1.21BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: -12.2%
$1.84B to $1.62BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +2.1%
61.9M to 63.2MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Filter by minute, hour, day or week
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between -2% and 2%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 8.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 692.2x — a high multiple relative to the current trailing profit.
This company has not reported enough of the required figures to calculate this score.
Holds 345,875 shares after this filing.
Sold on the open market — 1,200 shares at $240.94 ($289.1K)
Holds 47,671 shares after this filing.
Had shares withheld to cover taxes — 1,412 shares at $243.03 ($343.2K)
Holds 23,830 shares after this filing.
Had shares withheld to cover taxes — 15 shares at $241.20 ($3.6K)
Holds 23,815 shares after this filing.
Had shares withheld to cover taxes — 1,967 shares at $246.81 ($485.5K)
Holds 145,394 shares after this filing.
Sold on the open market — 2,000 shares at $243.03 ($486.1K)
Holds 143,394 shares after this filing.
Had shares withheld to cover taxes — 14 shares at $244.64 ($3.4K)
Holds 8,615 shares after this filing.
Had shares withheld to cover taxes — 1,692 shares at $241.39 ($408.4K)
Holds 6,923 shares after this filing.
Had shares withheld to cover taxes — 14 shares at $244.64 ($3.4K)
Holds 11,271 shares after this filing.
Had shares withheld to cover taxes — 1,692 shares at $241.39 ($408.4K)
Holds 9,579 shares after this filing.
Had shares withheld to cover taxes — 2,076 shares at $241.39 ($501.1K)
Holds 25,258 shares after this filing.
Had shares withheld to cover taxes — 16 shares at $244.64 ($3.9K)
Holds 25,242 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 14,687 shares ($3.4M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 2,000 shares ($472.8K) on or after .
Shares originally obtained via Restricted Stock.
Filed notice to sell 6,000 shares ($1.4M) on or after .
Shares originally obtained via Stock Option.
Filed notice to sell 1,200 shares ($289.1K) on or after .
Shares originally obtained via Restricted Stock.
Filed notice to sell 2,691 shares ($664.2K) on or after .
Shares originally obtained via RESTRICTED STOCK VESTING.
Filed notice to sell 2,000 shares ($486.1K) on or after .
Shares originally obtained via Restricted Stock.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure
Signed a material agreement · Took on a direct financial obligation · Sold shares outside a public offering · Reported another event
Read the filingReported another event
Read the filingSigned a material agreement
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Revenue +15.5% · Operating margin +86.2 pts · Operating income turned positive — against Q2 FY2026
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q1 FY2026
Revenue +19.1% · Operating margin +37.7 pts · Operating income turned positive — against Q1 FY2026
Read the filingPublished results
Read the filingAnnual report for FY2025
Operating margin −27.7 pts · Operating income turned negative · Profit turned negative — against FY2024
Read the filingAnnual report for FY2025
Operating margin −27.7 pts · Operating income turned negative · Profit turned negative — against FY2024
Read the filingPublished results
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q3 FY2025
Revenue +6.7% · Operating margin −19.6 pts · Operating income -77.9% — against Q3 FY2024
Read the filingQ2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
Yahoo Finance ·
Primary sources and further research